ALPHAMAB-B(09966),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09966 ALPHAMAB-B

Market Closed 03-28 16:08:10

8.170

+0.780

+10.55%

High8.270	Low7.370	Vol7.29M
Open7.390	D1 Closing7.390	Amplitude12.18%
Mkt Cap7.86B	Tradable Cap7.86B	Total Shares962.00M
T/O57.85M	T/O Rate0.76%	Tradable Shares962.00M
P/B4.01	ROE9.49%	EPS0.18
52wk High8.270	52wk Low2.000	P/E44.17
Dividend0.00	Div.Yield0.00	ROA2.88%

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"09966","market":"HK","secType":"STK","nameCN":"ALPHAMAB-B","latestPrice":8.17,"timestamp":1743149290017,"preClose":7.39,"halted":0,"volume":7292000,"delay":0,"floatShares":961999999,"shares":961999999,"eps":0.18495355557111295,"marketStatus":"Market Closed","change":0.78,"latestTime":"03-28 16:08:10","open":7.39,"high":8.27,"low":7.37,"amount":57850307,"amplitude":0.121786,"askPrice":8.18,"askSize":10000,"bidPrice":8.1,"bidSize":30000,"shortable":3,"etf":0,"ttmEps":0.18188820436230127,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743384600000},"marketStatusCode":7,"adr":0,"listingDate":1576080000000,"exchange":"SEHK","adjPreClose":7.39,"openAndCloseTimeList":[[1743125400000,1743134400000],[1743138000000,1743148800000]],"volumeRatio":2.426945350422237,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09966","defaultTab":"news","newsList":[{"id":"2522185353","title":"Alphamab Oncology Full Year 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2522185353","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522185353?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 08:03","pubTimestamp":1743033839,"startTime":"0","endTime":"0","summary":"Alphamab Oncology ( HKG:9966 ) Full Year 2024 Results Key Financial Results Revenue: CN¥640.1m (up 193% from FY 2023...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/alphamab-oncology-full-year-2024-earnings-beats-expectations","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09966"],"gpt_icon":0},{"id":"2522202742","title":"Alphamab Oncology FY Revenue RMB 640.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522202742","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522202742?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:17","pubTimestamp":1742905028,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nPLX387201:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2520446634","title":"Alphamab Oncology Says Jskn003 Granted Therapy Designation By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2520446634","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520446634?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 09:05","pubTimestamp":1742259955,"startTime":"0","endTime":"0","summary":"March 18 (Reuters) - Alphamab Oncology <9966.HK>::*JSKN003 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION BY NMPA*Further company coverage: 9966.HK* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Inv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nRSDc2ywZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2517963731","title":"Alphamab Oncology to Turn to 2024 Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2517963731","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517963731?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 14:52","pubTimestamp":1741157539,"startTime":"0","endTime":"0","summary":"Alphamab Oncology  expects a profit of at least 150 million yuan for the year 2024, compared with a loss of around 210.6 million yuan a year prior, a Tuesday filing with the Hong Kong bourse said.The drugmaker attributed the anticipated turnaround to profit mainly to three license collaborations and sales revenue.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"2517956763","title":"BUZZ-HK-listed Alphamab Oncology jumps on expectation of first annual profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2517956763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517956763?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 11:58","pubTimestamp":1741147114,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed Alphamab Oncology jumps on expectation of first annual profit  ** Shares of Alphamab Oncology 9966.HK jump as much as 15.8% to HK$6.07, set for biggest one-day pct gain since February 27** Stock top pct gainer on healthcare index .HSCIH, which is up 1.1%** The oncology drugs developer expects to record a net profit of 150 mln yuan  for 2024 as compared to a loss of 210.6 mln yuan in 2023; this is the first time the company expects to achieve an annual profit** The Hang Seng Commerce & Industry Index .HSNC jumps 1.9%, Hang Seng Index .HSI rises 1.6%** Stock up 73.4% YTD    ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL2N3PO06W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"2516672802","title":"BRIEF-Alphamab Oncology Sees Profit Of Not Less Than RMB150.0 Million For Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2516672802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516672802?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:29","pubTimestamp":1741098563,"startTime":"0","endTime":"0","summary":"BRIEF-Alphamab Oncology Sees Profit Of Not Less Than RMB150.0 Million For YearMarch 4  - Alphamab Oncology 9966.HK:SEES PROFIT OF NOT LESS THAN RMB150.0 MILLION FOR YEAREXPECTED RESULT DUE TO THREE LICENSE COLLABORATIONS AND SALES REVENUE IN FYFurther company coverage: 9966.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2516620764","title":"Alphamab Oncology - Expected Result Due to Three License Collaborations and Sales Revenue in FY","url":"https://stock-news.laohu8.com/highlight/detail?id=2516620764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516620764?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:06","pubTimestamp":1741089999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0FF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2516207616","title":"Alphamab Oncology Sees  Profit of Not Less Than RMB150.0 Mln for Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2516207616","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516207616?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:06","pubTimestamp":1741089999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2514361098","title":"Market Participants Recognise Alphamab Oncology's (HKG:9966) Revenues Pushing Shares 88% Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2514361098","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514361098?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 08:40","pubTimestamp":1740703200,"startTime":"0","endTime":"0","summary":"Alphamab Oncology ( HKG:9966 ) shareholders would be excited to see that the share price has had a great month, posting...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/market-participants-recognise-alphamab-oncologys-hkg9966-rev","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09966"],"gpt_icon":0},{"id":"2510388782","title":"Even after rising 14% this past week, Alphamab Oncology (HKG:9966) shareholders are still down 78% over the past five years","url":"https://stock-news.laohu8.com/highlight/detail?id=2510388782","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510388782?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 11:45","pubTimestamp":1739245519,"startTime":"0","endTime":"0","summary":"Alphamab Oncology ( HKG:9966 ) shareholders should be happy to see the share price up 16% in the last month. But that...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/even-after-rising-14-this-past-week-alphamab-oncology-hkg996","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2494382035","title":"BRIEF-Alphamab Oncology Receives Approval From CDE China For JSKN003 To Initiate Phase III Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2494382035","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494382035?lang=en_us&edition=full_marsco","pubTime":"2024-12-27 15:25","pubTimestamp":1735284342,"startTime":"0","endTime":"0","summary":"Dec 27 (Reuters) - Alphamab Oncology   :   * APPROVAL FROM CDE CHINA FOR JSKN003 TO INITIATE A PHASE III- CLINICAL STUDY FOR TREATMENT OF OC Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2494826412","title":"Alphamab Oncology's Anti-Tumor Drug Gets NMPA's Nod for Phase III Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2494826412","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494826412?lang=en_us&edition=full_marsco","pubTime":"2024-12-27 13:36","pubTimestamp":1735277772,"startTime":"0","endTime":"0","summary":"Alphamab Oncology  said JSKN003 received approval from the Center for Drug Evaluation of China's National Medical Products Administration to initiate a phase III clinical study, according to Friday filing with the Hong Kong bourse.JSKN003 is a HER2-targeting ADC  that combines a topoisomerase I inhibitor with KN026  used to treat tumors. The drug linker is attached specifically to the antibody's N-glycosylation site using glycoside-specific conjugation, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["III","BK1574","09966","BK4134","BK1161"],"gpt_icon":0},{"id":"2494840927","title":"Alphamab Oncology - Approval From Cde China for Jskn003 to Initiate a Phase Iii- Clinical Study for Treatment of Oc","url":"https://stock-news.laohu8.com/highlight/detail?id=2494840927","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494840927?lang=en_us&edition=full_marsco","pubTime":"2024-12-27 12:01","pubTimestamp":1735272062,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241227:nFWN3NR06G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2494702883","title":"Alphamab Oncology's Anti-Tumor Drug Gets IND Approval from NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2494702883","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494702883?lang=en_us&edition=full_marsco","pubTime":"2024-12-26 11:25","pubTimestamp":1735183509,"startTime":"0","endTime":"0","summary":"Alphamab Oncology  said the Center for Drug Evaluation of China's National Medical Products Administration approved the new investigational drug application for its new anti-tumor drug after the phase I/II clinical trial, according to a Tuesday filing with the Hong Kong bourse.JSKN033-102 is a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate and PD-L1 immune checkpoint inhibitor, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"2492984537","title":"Breakeven On The Horizon For Alphamab Oncology (HKG:9966)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492984537","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492984537?lang=en_us&edition=full_marsco","pubTime":"2024-12-17 09:17","pubTimestamp":1734398241,"startTime":"0","endTime":"0","summary":"Alphamab Oncology ( HKG:9966 ) is possibly approaching a major achievement in its business, so we would like to shine...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/breakeven-on-the-horizon-for-alphamab-oncology-hkg9966","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2482203696","title":"Alphamab Oncology Presents Clinical Study Results for Tumor Treatment at Houston Cancer Meet","url":"https://stock-news.laohu8.com/highlight/detail?id=2482203696","media":"MT Newswires Live","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482203696?lang=en_us&edition=full_marsco","pubTime":"2024-11-11 17:53","pubTimestamp":1731318815,"startTime":"0","endTime":"0","summary":"Alphamab Oncology  presented the results of a phase 1/2 study of its JSKN033 treatment during a cancer immunotherapy summit in Houston, according to a Sunday filing with the Hong Kong Exchange.JSKN033 is indicated for HER2-expressing advanced or metastatic solid tumors.The study showed favorable anti-tumor activity while exhibiting safety, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2479429001","title":"Alphamab Oncology Receives Waivers for Company Secretary from Hong Kong Bourse","url":"https://stock-news.laohu8.com/highlight/detail?id=2479429001","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479429001?lang=en_us&edition=full_marsco","pubTime":"2024-10-29 16:23","pubTimestamp":1730190219,"startTime":"0","endTime":"0","summary":"Alphamab Oncology  said it received a waiver from the Hong Kong stock exchange to allow Cheng Qiulan to be appointed as company secretary, according to a Tuesday filing with the Hong Kong bourse.The bourse earlier deemed Cheng is not experienced enough or qualified for the position. The three-year waiver request states that Chan Lok Yee will assist Cheng during this period.The waiver may be revoked if there are any material violations of the terms, the filing added.Price : $3.96, Change: $+0.0100, Percent Change: +0.25%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","HKD","09966","BK4526","BK4585","BK4588","BK4023","BK1161"],"gpt_icon":0},{"id":"2471873006","title":"Hong Kong Stocks Surge as China's Property Sector Rescue Overshadows Weak PMI Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2471873006","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471873006?lang=en_us&edition=full_marsco","pubTime":"2024-09-30 16:55","pubTimestamp":1727686546,"startTime":"0","endTime":"0","summary":"Hong Kong stocks continued their upward trend on Monday, buoyed by optimism surrounding China's stimulus package aimed at rescuing the property market.The Hang Seng Index jumped 2.43%, or 501.38 point","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1587","MCHmain","LU1993786604.SGD","02833","IE0008369823.USD","LU0880133367.SGD","BK1575","IE0008368742.USD","02567","BK1161","LU1807302812.USD","513600","LU0326950275.SGD","BK1191","IE00B543WZ88.USD","BK1574","LU0501845795.SGD","LU1226287529.USD","HSI","LU1152091754.HKD","IE00BZ08YR35.GBP","BK1515","CFA.SI","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","BK1521","LU0067412154.USD","LU1008478684.HKD","HHImain","06608","IE00BZ08YS42.EUR","BK1583","IE00B031HY20.USD","LU0072913022.USD","SG9999004220.SGD","LU1152091168.USD","09966","LU1960683339.HKD","01093","LU0140636845.USD","BK1131"],"gpt_icon":0},{"id":"2471841434","title":"Alphamab Oncology's Unit Signs Licensing Agreement for Tumor Drug; Alphamab Shares Surge 39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2471841434","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471841434?lang=en_us&edition=full_marsco","pubTime":"2024-09-30 13:02","pubTimestamp":1727672551,"startTime":"0","endTime":"0","summary":"Alphamab Oncology  unit Jiangsu Alphamab Biopharmaceuticals signed a licensing agreement with Shanghai JMT-Bio Technology, a unit of CSPC Pharmaceutical Group , to develop, sell, and commercialize tumor-related drug JSKN003 in mainland China, according to a Sunday filing with the Hong Kong bourse.JMT-Bio will obtain the exclusive license and sublicense rights to develop, sell, offer, and commercialize JSKN003 and will be the sole authorized marketer holder. JMT-Bio will bear further clinical development expenses for the drug. Alphamab will have the right to supply the drug outside JMT-Bio's territory, including Hong Kong, Taiwan, and Macau.Alphamab will be entitled to 3.08 billion yuan, including 400 million yuan and 300 million in upfront and sales milestone payments. The company will also receive royalties on medication sales.The pharmaceutical stocks were up nearly 39% in recent trading, while CSPC Pharma's shares rose over 5%.Price : $4.24, Change: $+1.2, Percent Change: +38.56%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0326950275.SGD","LU0501845795.SGD","09966","BK4526","LU0067412154.USD","LU0880133367.SGD","BK1161","IE00BZ08YT58.USD","IE0008369823.USD","BK4585","LU1152091754.HKD","BK4588","LU1226287529.USD","LU1960683339.HKD","BK1515","IE00B543WZ88.USD","LU1152091168.USD","LU1807302812.USD","BK1574","BK4023","LU0140636845.USD","01093","IE00B5MMRT66.SGD","SG9999004220.SGD","HKD","BK1521","BK1191","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","LU1008478684.HKD","LU1993786604.SGD","LU0072913022.USD","IE0008368742.USD","IE00B031HY20.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alphamab.com","stockEarnings":[{"period":"1week","weight":0.1041},{"period":"1month","weight":0.6439},{"period":"3month","weight":1.2569},{"period":"6month","weight":1.6699},{"period":"1year","weight":0.8035},{"period":"ytd","weight":1.3343}],"compareEarnings":[{"period":"1week","weight":-0.0111},{"period":"1month","weight":-0.0152},{"period":"3month","weight":0.1661},{"period":"6month","weight":0.1354},{"period":"1year","weight":0.4162},{"period":"ytd","weight":0.1678}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Alphamab Oncology is an investment holding company primarily engaged in the biopharmaceutical business. The Company is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The Company has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The Company operates its businesses in both domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.121729},{"month":2,"riseRate":0.666667,"avgChangeRate":0.22886},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.032323},{"month":4,"riseRate":1,"avgChangeRate":0.117691},{"month":5,"riseRate":0.4,"avgChangeRate":-0.096701},{"month":6,"riseRate":0.4,"avgChangeRate":0.026634},{"month":7,"riseRate":0.2,"avgChangeRate":-0.0532},{"month":8,"riseRate":0.4,"avgChangeRate":0.041129},{"month":9,"riseRate":0.2,"avgChangeRate":0.094086},{"month":10,"riseRate":0.4,"avgChangeRate":-0.004359},{"month":11,"riseRate":0.6,"avgChangeRate":0.064609},{"month":12,"riseRate":0.6,"avgChangeRate":-0.004095}],"exchange":"SEHK","name":"ALPHAMAB-B","nameEN":"ALPHAMAB-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ALPHAMAB-B(09966),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ALPHAMAB-B(09966) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ALPHAMAB-B,09966,ALPHAMAB-B股票,ALPHAMAB-B股票老虎,ALPHAMAB-B股票老虎国际,ALPHAMAB-B行情,ALPHAMAB-B股票行情,ALPHAMAB-B股价,ALPHAMAB-B股市,ALPHAMAB-B股票价格,ALPHAMAB-B股票交易,ALPHAMAB-B股票购买,ALPHAMAB-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ALPHAMAB-B(09966),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ALPHAMAB-B(09966) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}